Related Experiment Video
Updated: Sep 21, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal Denervation for Uncontrolled Hypertension in a Patient With Mast Cell Activation Syndrome
Sri Nuvvula1, Maryyam Mian1, Avneet Singh2
1Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Background:
Renal denervation (RDN) is a treatment option for resistant hypertension.
Case Summary:
We present a 64-year-old woman with medication intolerance secondary to mast cell activation syndrome who presented with uncontrolled hypertension and underwent bilateral RDN. Her systolic and diastolic recordings measured using Dinamap device (GE Healthcare), decreased from 151 ± 7.6 and 75 ± 4.1 mm Hg to 126 ± 4.5 and 66 ± 2.8 mm Hg, respectively, at 3 months after her procedure (both P < 0.05).
Discussion:
We show that RDN can be used in patients with severe medication intolerance due to an autoimmune condition. We also highlight the utility of using office-automated testing, which allowed us to likely obtain more accurate multiple blood pressure readings over 15 minutes.
Take-Home Message:
This report highlights RDN's efficacy in a patient unable to tolerate pharmacological antihypertensive therapy and highlights the clinical utility of using automated blood pressure readings.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Vasodilators
